Sunshine Biopharma, Inc. (SBFM)
- Previous Close
2.8700 - Open
3.0000 - Bid 3.0800 x 100
- Ask 3.1200 x 100
- Day's Range
2.8729 - 3.1400 - 52 Week Range
2.4200 - 740.0000 - Volume
183,580 - Avg. Volume
163,494 - Market Cap (intraday)
3.795M - Beta (5Y Monthly) -1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-378.2500 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
300.00
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
sunshinebiopharma.com44
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SBFM
View MorePerformance Overview: SBFM
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SBFM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBFM
View MoreValuation Measures
Market Cap
3.51M
Enterprise Value
-7.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.14
Price/Book (mrq)
0.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.07%
Return on Assets (ttm)
-9.91%
Return on Equity (ttm)
-15.79%
Revenue (ttm)
30.48M
Net Income Avi to Common (ttm)
-3.68M
Diluted EPS (ttm)
-378.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
11.51M
Total Debt/Equity (mrq)
2.46%
Levered Free Cash Flow (ttm)
-11.57M